Cytoreductive Nephrectomy and Overall Survival of Patients with
Metastatic Renal Cell Carcinoma Treated with Targeted
Therapy-Data from the National Renis Registry

J 2020

Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry

POPRACH, Alexandr, Miloš HOLÁNEK, Renata CHLOUPKOVÁ, Radek LAKOMÝ, Michal STANÍK et. al.

Základní údaje

Originální název

Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry

Autoři

POPRACH, Alexandr (203 Česká republika, garant, domácí), Miloš HOLÁNEK (203 Česká republika, domácí), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Radek LAKOMÝ (203 Česká republika, domácí), Michal STANÍK (703 Slovensko, domácí), Ondřej FIALA (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), Kateřina KOPECKOVA (203 Česká republika), Milada ZEMANOVA (203 Česká republika), Igor KISS (203 Česká republika, domácí), Igor PENKA (203 Česká republika, domácí), Júlia BOHOŠOVÁ (703 Slovensko, domácí) a Tomáš BUCHLER (203 Česká republika)

Vydání

Cancers, BASEL, MDPI, 2020, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.639

Kód RIV

RIV/00216224:14110/20:00118629

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/cancers12102911

UT WoS

000584121600001

Klíčová slova anglicky

metastatic renal cell carcinoma; targeted therapy; cytoreductive nephrectomy; overall survival

Štítky

14110223, 14110811, 14110813, 14119612, rivok

Změněno: 15. 1. 2021 12:59, Mgr. Tereza Miškechová

Anotace

V originále

Simple Summary: The treatment of metastatic renal cell carcinoma is traditionally initiated with the removal of the diseased kidney with the tumor in many patients. However, there is ongoing controversy about the benefit of kidney removal if targeted therapy is used. The present paper analyses a large cohort of patients, and the results indicate that primary tumor removal should still be strongly considered in patients who are treated with targeted therapies. The role of cytoreductive nephrectomy (CN) in treatment of locally advanced or metastatic renal cell carcinoma (mRCC) in the era of targeted therapies (TT) is still not clearly defined. The study population consisted of 730 patients with synchronous mRCC. The RenIS (Renal carcinoma Information System) registry was used as the data source. The CN/TT cohort included patients having CN within 3 months from the mRCC diagnosis and subsequently being treated with TT, while the TT cohort included patients receiving TT upfront. Median progression-free survival from the first intervention was 6.7 months in the TT arm and 9.3 months in the CN/TT patients (p < 0.001). Median overall survival was 14.2 and 27.2 months, respectively (p < 0.001). Liver metastasis, high-grade tumor, absence of CN, non-clear cell histology, and MSKCC (Memorial Sloan-Kettering Cancer Center) poor prognosis status were associated with adverse treatment outcomes. According to the results of this retrospective study, patients who underwent CN and subsequently were treated with TT had better outcomes compared to patients treated with upfront TT. The results of the study support the use of CN in the treatment algorithm for mRCC.

Návaznosti

NV18-03-00554, projekt VaV

Název: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii

Investor: Ministerstvo zdravotnictví ČR, Molecular classification of renal cell carcinoma based on long noncoding RNAs expression and its implication for diagnosis, prognosis and therapy

NV19-08-00250, projekt VaV

Název: Proteotypová klasifikace renálního karcinomu ve vztahu k prognóze a terapeutické odpovědi

Investor: Ministerstvo zdravotnictví ČR, Proteotypová klasifikace renálního karcinomu ve vztahu k prognóze a terapeutické odpovědi

Citovat

POPRACH, Alexandr, Miloš HOLÁNEK, Renata CHLOUPKOVÁ, Radek LAKOMÝ, Michal STANÍK, Ondřej FIALA, Bohuslav MELICHAR, Kateřina KOPECKOVA, Milada ZEMANOVA, Igor KISS, Igor PENKA, Júlia BOHOŠOVÁ a Tomáš BUCHLER. Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry. Cancers. BASEL: MDPI, 2020, roč. 12, č. 10, s. 1-10. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers12102911.

@article{1698736,
   author = {Poprach, Alexandr and Holánek, Miloš and Chloupková, Renata and Lakomý, Radek and Staník, Michal and Fiala, Ondřej and Melichar, Bohuslav and Kopeckova, Kateřina and Zemanova, Milada and Kiss, Igor and Penka, Igor and Bohošová, Júlia and Buchler, Tomáš},
   article_location = {BASEL},
   article_number = {10},
   doi = {http://dx.doi.org/10.3390/cancers12102911},
   keywords = {metastatic renal cell carcinoma; targeted therapy; cytoreductive nephrectomy; overall survival},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry},
   url = {https://www.mdpi.com/2072-6694/12/10/2911},
   volume = {12},
   year = {2020}
}

TY  - JOUR
ID  - 1698736
AU  - Poprach, Alexandr - Holánek, Miloš - Chloupková, Renata - Lakomý, Radek - Staník, Michal - Fiala, Ondřej - Melichar, Bohuslav - Kopeckova, Kateřina - Zemanova, Milada - Kiss, Igor - Penka, Igor - Bohošová, Júlia - Buchler, Tomáš
PY  - 2020
TI  - Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry
JF  - Cancers
VL  - 12
IS  - 10
SP  - 1-10
EP  - 1-10
PB  - MDPI
SN  - 20726694
KW  - metastatic renal cell carcinoma
KW  - targeted therapy
KW  - cytoreductive nephrectomy
KW  - overall survival
UR  - https://www.mdpi.com/2072-6694/12/10/2911
L2  - https://www.mdpi.com/2072-6694/12/10/2911
N2  - Simple Summary: The treatment of metastatic renal cell carcinoma is traditionally initiated with the removal of the diseased kidney with the tumor in many patients. However, there is ongoing controversy about the benefit of kidney removal if targeted therapy is used. The present paper analyses a large cohort of patients, and the results indicate that primary tumor removal should still be strongly considered in patients who are treated with targeted therapies. The role of cytoreductive nephrectomy (CN) in treatment of locally advanced or metastatic renal cell carcinoma (mRCC) in the era of targeted therapies (TT) is still not clearly defined. The study population consisted of 730 patients with synchronous mRCC. The RenIS (Renal carcinoma Information System) registry was used as the data source. The CN/TT cohort included patients having CN within 3 months from the mRCC diagnosis and subsequently being treated with TT, while the TT cohort included patients receiving TT upfront. Median progression-free survival from the first intervention was 6.7 months in the TT arm and 9.3 months in the CN/TT patients (p < 0.001). Median overall survival was 14.2 and 27.2 months, respectively (p < 0.001). Liver metastasis, high-grade tumor, absence of CN, non-clear cell histology, and MSKCC (Memorial Sloan-Kettering Cancer Center) poor prognosis status were associated with adverse treatment outcomes. According to the results of this retrospective study, patients who underwent CN and subsequently were treated with TT had better outcomes compared to patients treated with upfront TT. The results of the study support the use of CN in the treatment algorithm for mRCC.
ER  -

POPRACH, Alexandr, Miloš HOLÁNEK, Renata CHLOUPKOVÁ, Radek LAKOMÝ, Michal STANÍK, Ondřej FIALA, Bohuslav MELICHAR, Kateřina KOPECKOVA, Milada ZEMANOVA, Igor KISS, Igor PENKA, Júlia BOHOŠOVÁ a Tomáš BUCHLER. Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry. \textit{Cancers}. BASEL: MDPI, 2020, roč.~12, č.~10, s.~1-10. ISSN~2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers12102911.

Podrobný výpis o publikaci